Observes lupus patients treated with anifrolumab in routine care
Follows adults with lupus who receive anifrolumab alongside standard treatment in routine care.
Plain-language title generated from the registry record
Registry title: INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
Key facts
- Where
- Aktobe, Almaty, Astana, Pavlodar, Semey, and Shymkent, KazakhstanSee the 6 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with systemic lupus erythematosus (SLE) who have been prescribed anifrolumab for the first time in routine care.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- SLE that meets the 2019 EULAR/ACR criteria for SLE at study entry.
- Earlier treatment
- Anifrolumab prescribed for the first time. People who took it before in a clinical trial or early access program cannot join.
Main reasons for not taking part
- Taking part now in an anifrolumab early access or compassionate use program, or in a trial of an investigational product
- Earlier anifrolumab use in a clinical trial or early access program
- Severe or fast-worsening lupus kidney disease (Class III or IV glomerulonephritis needing induction therapy), or isolated Class V lupus nephritis
- Active severe or unstable lupus affecting the brain or nerves (neuropsychiatric lupus)
- A condition that limits understanding the consent form or completing the patient questionnaires
Read by machine on 9 November 2026.
Where in Kazakhstan
- AktobeHospital not named in the registryNo longer taking part
- AlmatyHospital not named in the registryNo longer taking part
- AstanaHospital not named in the registryNo longer taking part
- PavlodarHospital not named in the registryNo longer taking part
- SemeyHospital not named in the registryNo longer taking part
- ShymkentHospital not named in the registryNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06314282
- Record updated
- 1 September 2026
- Original description
INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations. The study will use standardized objectives, inclusion/exclusion criteria and outcome measures across all countries participating in this study including GCC (Qatar, KSA), Mexico, CAMCAR (Costa Rica, Panama, Dominican Republic), Colombia, Argentina, Taiwan, and Egypt, and any other countries that may be included in the study, in order to facilitate a comparison and analysis across all countries included in this study.Read full original descriptionShow less
INTERSTELLAR - Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice
INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations. The study will use standardized objectives, inclusion/exclusion criteria and outcome measures across all countries participating in this study including GCC (Qatar, KSA), Mexico, CAMCAR (Costa Rica, Panama, Dominican Republic), Colombia, Argentina, Taiwan, and Egypt, and any other countries that may be included in the study, in order to facilitate a comparison and analysis across all countries included in this study.
Inclusion: Aged 18 years or older at study enrolment; Fulfilled the 2019 EULAR/ACR criteria1 for SLE at the time of study entry; Prescribed anifrolumab for their SLE treatment for the first time, according to approved country-specific label; It is important to note that a physician decision to prescribe anifrolumab will need to occur prior to any study-related discussion; In countries where prescription reimbursements are authorized on a case-by-case basis, authorization (ie, patient access to treatment) will be required for study entry; Provided informed consent to participate in the study; Willing and able to participate in all required study evaluations and procedures.
Exclusion: Currently participating in an anifrolumab early access/compassionate use program or an interventional clinical trial with an investigational product; Previous exposure to anifrolumab as part of a clinical trial or early access program; Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy (mycophenolate mofetil [MMF]/cyclophosphamide [CYC] + high dose steroids), isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus; Any other condition which the investigator deems to limit a patient's ability to understand the informed consent or complete the PROs.